Addressing Common Concerns About GLP-1 Safety, Legality, and Insurance Coverage 1
(A 2022 clinical trial published in the New England Journal of Medicine found that roughly 80% of people taking Zepbound did.) Research and obesity medicine specialists have identified a few common patterns for when symptoms tend to flare up: Early on, especially during the first few weeks Within 48 hours of an injection After a dose increase Individual bouts of nausea, diarrhea and vomiting often pass within a few days, though constipation can stick around much longer
You should also be cautious if you have a history of dizziness, fainting, dehydration, very low blood pressure, heart rhythm concerns, or rapid changes in weight
They attached a fatty acid chain to one of the analogues, liraglutide (Victoza, Saxenda), which enabled it to bind to the blood protein albumin, resulting in slower absorption and preventing it from being cleaved by DPP-4 [6,7]
These can be GLP-1 therapies, non-GLP-1 therapies, or both
Topline results released last month from the Phase III ATTAIN-MAINTAIN trial (NCT06584916) found that over 52 weeks, orforglipron achieved the primary endpoint in producing superior percent maintenance of weight loss vs
